Floatz logo

ONATASERTIB

Diffuse Large B-Cell Lymphoma

CelgeneSmall moleculePhase 1/2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
73/ 100

Competitive context

271 Active assets in the Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

ONATASERTIB is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical CancerDormant
CC
Indicative ·
45 / 100
View asset →
carcinoid tumorDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →